Addiction & Substance Use

Why are older patients turning to cannabis for symptom relief?

The FDA has authorized key modifications to the administration protocol for injectable long-acting opioid use disorder treatment buprenorphine.

A new patent was issued for Adial Pharmaceuticals’ identification of patients with specific genetic markers linked to substance use disorders and treatment with AD04.

At the beginning of this year, US Surgeon General Vivek H. Murthy, MD, MBA, issued a health advisory warning about the link between alcohol use and the risk of cancer. Learn more about its implications for psychiatry here.

Here are highlights from this week in Psychiatric Times, including FDA news and a look back at Psychiatric Times through the years.

New positive results of a pharmacokinetics study of AD04 for alcohol use disorder confirms the near micro-dosing regimen planned for upcoming trials.

From his own recovery to leading Illinois Recovery Center, Christopher Schenewerk, MD, shares he now champions peer support, naltrexone, and long-term care.

Check out new positive topline results from the open-label phase 2A study of BPL-003 in participants with moderate-to-severe alcohol use disorder.

A transformative shift in addiction treatment and advocating for evidence-based approaches like naltrexone to offer personalized recovery paths beyond traditional abstinence models may be in the future for addiction treatment.

Struggling with alcohol use or concerned about early signs of addiction? Identifying unhealthy drinking patterns early can make a difference.

Here are highlights from this week in Psychiatric Times, including FDA approvals and conference coverage.

A professional's battle with alcoholism escalated from social drinking to daily dependence, impacting work and relationships until a pivotal moment led to seeking rehab and recovery.

What are some of the best medical interventions for alcohol use disorder?

Learn how clinicians can better recognize, diagnose, and support patients struggling with addiction through proactive screening and honest conversations.

Understanding the complex relationship between substance use and mental health is critical to providing thorough and well-informed evaluations. Let's take a look at the relationship between cannabis and criminal responsibility.

How can psychiatric clinicians ensure their practices are accessible to patients with disabilities?

While complete abstinence is a good goal, what other clinically meaningful endpoints are there for patients with substance use disorders? Learn more in this ACNP 2024 Annual Meeting session!

Inhalant use disorder is a form of substance use disorder characterized by the intentional inhalation of volatile substances for their psychoactive effects.

Novel treatment for cocaine use disorder? Researchers performed a randomized, double-blind, placebo-controlled trial of lorcaserin.

This book seeks to reduce the stigma surrounding teen pregnancy.

Learn more about the latest viral substance abuse trend.

In this CME article, learn how best to provide end-of-life care to patients with psychiatric disorders.

Assisted outpatient treatment is not intended to replace comprehensive, easy-to-access, voluntary treatment. Here's why we need it, according to one expert.

When psychiatrists fully embrace psychopharmacological interventions as integral components of addiction treatment, patients can begin a journey toward sustainable recovery.

Tomorrow, August 31, is Overdose Awareness Day. What can you be doing to help prevent overdose deaths?